Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of C019199 plus sintilimab in advanced malignant solid tumors
CTR20231960Phase 2Active
- Sponsor
- Haixi New Pharma
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of C019199, sintilimab in Nonhematologic neoplasms, colorectal cancer (CRC), gastric cancer (GC), Esophageal Squamous Cell Carcinoma (ESCC), pancreatic cancer (PC), sponsored by Haixi New Pharma. Started Jul 2023; status: active.
02
Drugs
C019199sintilimab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)gastric cancer (GC)Esophageal Squamous Cell Carcinoma (ESCC)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20231960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231960.